LOS ANGELES — This city is now home to its very first biotech venture firm: Dr. Beth Seidenberg, a general partner at Kleiner Perkins, will now be heading up a $320 million fund called Westlake Village BioPartners dedicated exclusively to the life sciences — and, potentially, helping build up the LA area as a new biotech hub.

Seidenberg, former chief medical officer of Amgen (AMGN), is bringing on board Sean Harper — who by January will end his tenure as R&D head at the Los Angeles-area biotech. Some of the better-known companies in Seidenberg’s portfolio include ovarian cancer therapeutics company Tesaro, allogeneic T cell company Atara Biotherapeutics (ATRA), and epigenetics player Epizyme (EPZM).

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy